Cargando…
Targeting bone morphogenetic protein signalling in midbrain dopaminergic neurons as a therapeutic approach in Parkinson's disease
Parkinson's disease (PD) is the second most common neurodegenerative disease, characterized by the degeneration of midbrain dopaminergic (mDA) neurons and their axons, and aggregation of α-synuclein, which leads to motor and late-stage cognitive impairments. As the motor symptoms of PD are caus...
Autores principales: | O'Keeffe, Gerard W., Hegarty, Shane V., Sullivan, Aideen M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373244/ https://www.ncbi.nlm.nih.gov/pubmed/32714578 http://dx.doi.org/10.1042/NS20170027 |
Ejemplares similares
-
Targeting transcriptional regulators to regenerate midbrain dopaminergic axons in Parkinson's disease
por: Hegarty, Shane V., et al.
Publicado: (2017) -
Protocol for evaluation of neurotrophic strategies in Parkinson’s disease-related dopaminergic and sympathetic neurons in vitro
por: Hegarty, Shane V., et al.
Publicado: (2016) -
Inhibition of miR-181a promotes midbrain neuronal growth through a Smad1/5-dependent mechanism: implications for Parkinson’s disease
por: Hegarty, Shane V., et al.
Publicado: (2018) -
Zeb2 is a negative regulator of midbrain dopaminergic axon growth and target innervation
por: Hegarty, Shane V., et al.
Publicado: (2017) -
The Epigenome as a therapeutic target for Parkinson's disease
por: Hegarty, Shane V., et al.
Publicado: (2016)